Novo Nordisk A/S Sponsored ADR (NVO)
Novo Nordisk A/S Q2 Earnings Call Highlights
Novo Nordisk A/S NYSE: NVO reported second-quarter adjusted sales growth of 7% at constant exchange rates, supported by GLP-1 volume growth across its obesity and diabetes franchises, while lower realized prices and manufacturing-related costs weighed on margins.
Novo Nordisk: Dismal Q2 Earnings, Operational Frailties Warrant Rating Downgrade
Novo Nordisk A/S receives a Sell rating due to falling profits, weak revenue growth, and operational missteps despite its blockbuster semaglutide franchise. NVO's 2026 guidance signals flat to negative sales and operating profit growth, contrasting sharply with Eli Lilly's robust growth trajectory and diversified pipeline. Patent expiries, manufacturing setbacks, and pipeline disappointments undermine NVO's first-mover advantage in obesity and diabetes, while competition intensifies.
NVO Q2 Earnings Call Centers on Wegovy Pill and Outlook Lift
Novo Nordisk lifts its 2026 outlook as Wegovy pill demand accelerates, even as U.S. pricing, patent losses and competition pressure the second half.
NVO Stock Down Despite Q2 Earnings and Sales Beat on GLP-1 Growth
Novo Nordisk beats Q2 earnings and sales estimates as GLP-1 demand grows, but pricing pressure, outlook concerns and pipeline setbacks sent shares lower.
Novo Nordisk: Opportunistically Adding To A Long-Term Winner (Q2 Review)
Novo Nordisk A/S delivered mixed Q2 results with 7% adjusted net sales growth and an upward revision to full-year guidance, yet shares declined 6%. NVO's obesity segment, led by Wegovy pill, is a key growth driver, with new markets and strong US uptake offsetting pricing pressure. Margins compressed due to U.S. price reductions, but NVO maintains robust profitability, strong free cash flow, and a solid balance sheet supporting R&D and shareholder returns.
Novo Nordisk CEO Remains Open to Bolt-On Acquisitions, But Rules out Transformative Deals
Chief Executive Mike Doustdar's comments come amid sector focus on M&A and after Novo Nordisk made two disclosures in recent days on its future pipeline that disappointed investors.
Novo Nordisk's raised forecast fails to change the debate over its obesity business
Novo Nordisk raised its full year outlook late Tuesday. Analysts said the better-than-expected quarter benefited from rebate adjustments and other temporary factors, while obesity drug sales were largely in line with expectations and oral Wegovy slightly missed forecasts.
Novo CEO faces investor grilling after outlook hike soured by pipeline concerns
Novo Nordisk CEO Mike Doustdar faces investors and analysts on Wednesday under pressure to restore confidence in the drugmaker's longer-term growth prospects after an upgraded 2026 outlook failed to reassure markets.
Novo Nordisk stock falls despite outlook hike as Wegovy sales miss hopes
US-listed shares of Novo Nordisk fell more than 6% on Tuesday after the Danish drugmaker released its second-quarter financial results and updated its full-year outlook a day ahead of its scheduled earnings announcement, with investors focusing on softer-than-expected sales of its oral Wegovy weight-loss drug. Novo Nordisk's American depositary receipts declined despite the company narrowing the expected decline in its full-year sales and operating profit guidance.
Novo Nordisk Raises Earnings Guidance. The Stock Sinks.
The Danish drugmaker continues to rely on the success of semaglutide, branded as Wegovy for weight loss and Ozempic for diabetes.
Novo Nordisk shares slide after guidance disappoints investors
U.S.-traded shares of Novo Nordisk dropped more than 5% after the Danish drugmaker released guidance that appeared to disappoint investors. Novo Nordisk hiked its outlook, citing the strength of its Wegovy pill and higher-dose injection.
Wegovy Maker Novo Nordisk Lifts Guidance After Second-Quarter Boost
The Danish drugmaker said annual sales and operating profit should fall less than it previously expected following a boost in the second quarter.
